Addus HomeCare (ADUS) Stock Price, News & Analysis

Company Overview

Addus HomeCare (NASDAQ: ADUS) is a leading provider of home and community-based care services for elderly, disabled, and medically complex individuals across the United States. Through a network of company-owned and franchise locations, the company delivers a broad spectrum of non-medical personal care and licensed home health services designed to support clients’ independence and quality of life.

The company’s core offerings include personal care assistance—covering daily living activities, medication reminders, and light housekeeping—and skilled home health services delivered under the supervision of registered nurses and licensed therapists. Addus HomeCare also provides private duty nursing, hospice and palliative care, and specialized programs for chronic conditions, Alzheimer’s disease, and pediatric therapy needs. Telehealth solutions and care coordination tools are integrated to enhance clinical oversight and patient engagement.

Tracing its roots to operations established in 1970, Addus HomeCare has grown through strategic acquisitions and organic expansion to serve clients in approximately 30 states. Headquartered in Charlotte, North Carolina, the company leverages a veteran executive leadership team with deep expertise in home health care delivery, regulatory compliance, and operational excellence. Addus HomeCare remains committed to advancing community-based services that enable individuals to “age in place” with dignity and comfort.

Key Stats

• Today's Range: $92.64 to $94.92
• 50-Day Range: $88.49 to $99.57
• 52-Week Range: $87.95 to $124.43
• Volume: 222,283 shs
• Average Volume: 187,840 shs
• Market Capitalization: $1.74 billion
• P/E Ratio: 17.24
• Dividend Yield: N/A
• Price Target: $131.00
• Consensus Rating: Moderate Buy

Addus HomeCare Stock Analysis - MarketRank™

Addus HomeCare scored higher than 76% of companies evaluated by MarketBeat, and ranked 120th out of 862 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Addus HomeCare has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 1 strong buy rating, 6 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Addus HomeCare has a consensus price target of $131.00, representing about 40.4% upside from its current price of $93.28.

Amount of Analyst Coverage

Addus HomeCare has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 8.17%

Earnings Growth

Earnings for Addus HomeCare are expected to grow by 8.17% in the coming year, from $6.24 to $6.75 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Addus HomeCare is 17.24, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.74.

Price to Earnings Ratio vs. Sector

The P/E ratio of Addus HomeCare is 17.24, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.21.

Price to Earnings Growth Ratio

Addus HomeCare has a PEG Ratio of 1.28. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Addus HomeCare has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.38% of the float of Addus HomeCare has been sold short.

Short Interest Ratio / Days to Cover

Addus HomeCare has a short interest ratio ("days to cover") of 5.04.

Change versus previous month

Short interest in Addus HomeCare has recently increased by 5.19%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Addus HomeCare does not currently pay a dividend.

Dividend Growth

Addus HomeCare does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.79

News Sentiment

Addus HomeCare has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Addus HomeCare this week, compared to 4 articles on an average week.

Search Interest

2 people have searched for ADUS on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Addus HomeCare to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Addus HomeCare insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $63,163.00 in company stock.

Percentage Held by Insiders

4.10% of the stock of Addus HomeCare is held by insiders.

Percentage Held by Institutions

95.35% of the stock of Addus HomeCare is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/04/2026
• Today: 6/14/2026
• Next Earnings (Estimated): 8/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - OUTP/HM CRE
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:ADUS
• CIK: 1468328
• Web: www.addus.com
• Phone: (469) 535-8200
• Fax: 630-487-2707
• Employees: 50,659
• Year Founded: 1979

Price Target and Rating

• Average Price Target for Addus HomeCare: $131.00
• High Price Target: $145.00
• Low Price Target: $92.00
• Potential Upside/Downside: +40.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.70
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): $5.41
• Trailing P/E Ratio: 17.24
• Forward P/E Ratio: 14.95
• P/E Growth: 1.28
• Net Income: $95.91 million
• Net Margins: 6.89%
• Pretax Margin: 9.17%
• Return on Equity: 9.80%
• Return on Assets: 7.34%

Debt

• Debt-to-Equity Ratio: 0.08
• Current Ratio: 1.83
• Quick Ratio: 1.83

Sales & Book Value

• Annual Sales: $1.42 billion
• Price / Sales: 1.22
• Cash Flow: $6.50 per share
• Price / Cash Flow: 14.36
• Book Value: $58.72 per share
• Price / Book: 1.59

Miscellaneous

• Outstanding Shares: 18,670,000
• Free Float: 17,900,000
• Market Cap: $1.74 billion
• Optionable: Optionable
• Beta: 0.89